Blood Res.  2021 Mar;56(1):26-30. 10.5045/br.2021.2020146.

Optimal panel of immunohistochemistry for the diagnosis of B-cell non-Hodgkin lymphoma using bone marrow biopsy: a tertiary care center study

Affiliations
  • 1Department of Pathology Pt. B. D. Sharma PGIMS, Rohtak, India.
  • 2Department of Medicine, Pt. B. D. Sharma PGIMS, Rohtak, India.

Abstract

Background
Morphological diagnosis of non-Hodgkin lymphoma (NHL) is usually based on lymph node biopsy. Bone marrow biopsy (BMB) is important for staging, and morphology alone can be challenging for subtyping. Immunohistochemistry (IHC) allows a more precise diagnosis and characterization of NHL using monoclonal antibodies. However, there is a need for a minimal panel that can provide maximum information at an affordable cost.
Methods
All newly diagnosed cases of B-cell NHL with bone marrow infiltration between 2017 and 2019 were included. BMB was the primary procedure for diagnosing B-cell NHL. Subtyping of lymphomas was performed by immunophenotyping using a panel of monoclonal antibodies on IHC. The primary diagnostic panel of antibodies for B-cell NHL included CD19, CD20, CD79, CD5, CD23, CD10, Kappa, and Lambda. The extended panel of antibodies for further subtyping included CD30, CD45, CD56, Cyclin D1, BCL2, and BCL6.
Results
All cases of B-cell NHL were classified into the chronic lymphocytic leukemia (CLL) and non-CLL groups based on morphology and primary IHC panel. In the CLL group, the most significant findings were CD5 expression, CD23 expression, dim CD79 expression, and weak surface immunoglobulin (Ig) positivity. In the non-CLL group, they were CD5 expression, positive or negative CD23 expression, strong CD79 expression, and strong surface Ig expression. An extended panel was used for further subtyping of non-CLL cases, which comprised CD10, Cyclin D1, BCL2, and BCL6.
Conclusion
We propose a two-tier approach for immunophenotypic analysis of newly diagnosed B-cell NHL cases with a minimum primary panel including CD5, CD23, CD79, Kappa, and Lambda for differentiation into CLL/non-CLL group and Kappa and Lambda for clonality assessment. An extended panel may be used wherever required for further subtyping of non-CLL.

Keyword

Non-Hodgkin lymphoma; Immunohistochemistry; Chronic lymphocytic leukemia; Non-chronic lymphocytic leukemia; Bone marrow biopsy

Figure

  • Fig. 1 Immunohistochemical profile of chronic lymphocytic leukemia showing CD19+, CD20+, CD5+, CD23+, CD79-, non-specific Lambda (immunohistochemistry, ×400).

  • Fig. 2 Immunohistochemical profile of mantle cell lymphoma showing CD5+, CD79+, Cyclin D1+, CD23- (immunohistochemistry, ×400).

  • Fig. 3 Immunohistochemical profile of follicular lymphoma showing CD19+ in the lymphoid follicle, CD10+ in the lymphoid follicle, BCL2+ in the lymphoid follicle, CD5-B cells in the lymphoid follicle with CD5+ scattered T-cells in the background (immunohisto-chemistry, ×400).


Reference

1. Zelenetz AD, Abramson JS, Advani RH, et al. 2010; NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 8:288–334. DOI: 10.6004/jnccn.2010.0021. PMID: 20202462.
2. Sah SP, Matutes E, Wotherspoon AC, Morilla R, Catovsky D. 2003; A comparison of flow cytometry, bone marrow biopsy, and bone marrow aspirates in the detection of lymphoid infiltration in B cell disorders. J Clin Pathol. 56:129–32. DOI: 10.1136/jcp.56.2.129. PMID: 12560392. PMCID: PMC1769888.
3. Okaly GV, Nargund AR, E V, Jayanna PK, Juvva CR, Prabhudesai S. 2013; Chronic lymphoproliferative disorders at an Indian tertiary cancer centre - the panel sufficiency in the diagnosis of chronic lymphocytic leukaemia. J Clin Diagn Res. 7:1366–71. DOI: 10.7860/JCDR/2013/5088.3130. PMID: 23998067. PMCID: PMC3749637.
4. Fineberg S, Marsh E, Alfonso F, et al. 1993; Immunophenotypic evaluation of the bone marrow in non-Hodgkin's lymphoma. Hum Pathol. 24:636–42. DOI: 10.1016/0046-8177(93)90244-B. PMID: 8505041.
5. Horny HP, Wehrmann M, Griesser H, Tiemann M, Bültmann B, Kaiserling E. 1993; Investigation of bone marrow lymphocyte subsets in normal, reactive, and neoplastic states using paraffin-embedded biopsy specimens. Am J Clin Pathol. 99:142–9. DOI: 10.1093/ajcp/99.2.142. PMID: 8438787.
6. Bluth RF, Casey TT, McCurley TL. 1993; Differentiation of reactive from neoplastic small-cell lymphoid aggregates in paraffin-embedded marrow particle preparations using L-26 (CD20) and UCHL-1 (CD45RO) monoclonal antibodies. Am J Clin Pathol. 99:150–6. DOI: 10.1093/ajcp/99.2.150. PMID: 7679873.
7. Hendry S, Salgado R, Gevaert T, et al. 2017; Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: Part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol. 24:311–35. DOI: 10.1097/PAP.0000000000000161. PMID: 28777143. PMCID: PMC5638696.
8. Rao IS. 2010; Role of immunohistochemistry in lymphoma. Indian J Med Paediatr Oncol. 31:145–7. DOI: 10.4103/0971-5851.76201. PMID: 21584221. PMCID: PMC3089924.
9. Dewan K, Mann N, Chatterjee T. 2015; Comparing flow cytometry immunophenotypic and immunohistochemical analyses in diagnosis and prognosis of chronic lymphoproliferative disorders: experience from a Tertiary Care Center. Clin Cancer Investig J. 4:707–12. DOI: 10.4103/2278-0513.165524.
10. Leers MP, Theunissen PH, Ramaekers FC, Schutte B, Nap M. 2000; Clonality assessment of lymphoproliferative disorders by multiparameter flow cytometry of paraffin-embedded tissue: an additional diagnostic tool in surgical pathology. Hum Pathol. 31:422–7. DOI: 10.1053/hp.2000.6551. PMID: 10821487.
11. Abdel-Ghafar AA, El Din El Telbany MA, Mahmoud HM, El-Sakhawy YN. 2012; Immunophenotyping of chronic B-cell neoplasms: flow cytometry versus immunohistochemistry. Hematol Rep. 4:e3. DOI: 10.4081/hr.2012.e3. PMID: 22567217. PMCID: PMC3343452.
Full Text Links
  • BR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr